Review: taking Depakote er and Clozaril together


Summary

Drug interactions are reported among people who take Depakote er and Clozaril together. This review analyzes the effectiveness and drug interactions between Depakote er and Clozaril. It is created by eHealthMe based on reports of 2,844 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Depakote Er

Depakote er has active ingredients of divalproex sodium. It is often used in bipolar disorder. (latest outcomes from Depakote er 4,447 users)

Clozaril

Clozaril has active ingredients of clozapine. It is often used in schizophrenia. (latest outcomes from Clozaril 34,567 users)

On Sep, 18, 2016

2,844 people who take Depakote Er, Clozaril are studied.


Number of reports submitted per year:

Depakote er and Clozaril drug interactions.

Drug effectiveness over time:

Depakote Er:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 2 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 3 people)
  • 5 - 10 years: 50.0% - (3 of 6 people)
  • 10+ years: 0.0% - (0 of 2 people)
  • not specified: 0.0% - (0 of 0 people)
Clozaril:
  • < 1 month: 100.0% - (2 of 2 people)
  • 1 - 6 months: 100.0% - (2 of 2 people)
  • 6 - 12 months: 100.0% - (2 of 2 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 2 people)
  • 5 - 10 years: 0.0% - (0 of 2 people)
  • 10+ years: 50.0% - (1 of 2 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Depakote Er:
  • female: 28.0% - (2 of 7 people)
  • male: 16.0% - (1 of 6 people)
Clozaril:
  • female: 71.0% - (5 of 7 people)
  • male: 40.0% - (2 of 5 people)

Drug effectiveness by age:

Depakote Er:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 1 people)
  • 20-29: 75.0% - (3 of 4 people)
  • 30-39: 0.0% - (0 of 3 people)
  • 40-49: 0.0% - (0 of 2 people)
  • 50-59: 0.0% - (0 of 2 people)
  • 60+: 0.0% - (0 of 1 people)
Clozaril:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 1 people)
  • 20-29: 100.0% - (3 of 3 people)
  • 30-39: 66.0% - (2 of 3 people)
  • 40-49: 50.0% - (1 of 2 people)
  • 50-59: 50.0% - (1 of 2 people)
  • 60+: 0.0% - (0 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • granulocytopenia
  • pyrexia
  • tachycardia
  • oxygen saturation decreased
  • white blood cell count decreased
  • body temperature increased
  • confusional state
  • dyspnoea
  • overdose
  • agranulocytosis
1 - 6 months:
  • granulocytopenia
  • agranulocytosis
  • neutropenia
  • leukopenia
  • white blood cell count decreased
  • white blood cell count increased
  • pyrexia
  • neutrophil count decreased
  • diarrhoea
  • vomiting
6 - 12 months:
  • granulocytopenia
  • leukopenia
  • neutropenia
  • agranulocytosis
  • white blood cell count decreased
  • agitation
  • death
  • vomiting
  • white blood cell count increased
  • cardiac arrest
1 - 2 years:
  • granulocytopenia
  • neutropenia
  • white blood cell count decreased
  • leukopenia
  • diarrhoea
  • agitation
  • vomiting
  • blood triglycerides increased
  • diabetes mellitus
  • white blood cell count increased
2 - 5 years:
  • granulocytopenia
  • leukopenia
  • neutropenia
  • pneumonia
  • convulsion
  • constipation
  • neutrophil count decreased
  • fall
  • blood creatine phosphokinase increased
  • death
5 - 10 years:
  • granulocytopenia
  • white blood cell count decreased
  • leukopenia
  • malaise
  • neutropenia
  • neutrophil count decreased
  • fall
  • agranulocytosis
  • cardiac arrest
  • confusional state
10+ years:
  • agranulocytosis
  • pneumonia
  • asthenia
  • convulsion
  • dyspnoea
  • neutropenia
  • obesity
  • pancytopenia
  • pyrexia
  • thrombocytopenia
not specified:
  • granulocytopenia
  • neutropenia
  • pyrexia
  • white blood cell count decreased
  • pneumonia
  • death
  • type 2 diabetes mellitus
  • leukopenia
  • diabetes mellitus
  • sedation

Most common drug interactions by gender *:

female:
  • granulocytopenia
  • pyrexia
  • leukopenia
  • diabetes mellitus
  • type 2 diabetes mellitus
  • neutropenia
  • agranulocytosis
  • tachycardia
  • white blood cell count increased
  • white blood cell count decreased
male:
  • granulocytopenia
  • neutropenia
  • white blood cell count decreased
  • pyrexia
  • convulsion
  • leukopenia
  • pneumonia
  • death
  • neutrophil count decreased
  • psychotic disorder

Most common drug interactions by age *:

0-1:
  • cerebrovascular accident
  • convulsion neonatal
  • drug exposure during pregnancy
  • muscular weakness
  • neoplasm malignant
  • tremor
2-9:
  • granulocytopenia
  • neutrophil percentage decreased
  • emotional disorder
  • frontotemporal dementia
  • haematoma
  • petit mal epilepsy
  • apnoea
  • bone disorder
  • dry skin
  • foetal exposure during pregnancy
10-19:
  • granulocytopenia
  • neutropenia
  • vomiting
  • hyperhidrosis
  • white blood cell count decreased
  • agitation
  • pyrexia
  • white blood cell count increased
  • agranulocytosis
  • weight increased
20-29:
  • granulocytopenia
  • pyrexia
  • psychotic disorder
  • vomiting
  • leukopenia
  • agitation
  • convulsion
  • weight increased
  • neutropenia
  • neutrophil count decreased
30-39:
  • granulocytopenia
  • convulsion
  • type 2 diabetes mellitus
  • neutropenia
  • pyrexia
  • weight increased
  • renal failure chronic
  • diabetes mellitus
  • obesity
  • psychotic disorder
40-49:
  • granulocytopenia
  • neutropenia
  • diabetes mellitus
  • leukopenia
  • type 2 diabetes mellitus
  • white blood cell count decreased
  • pyrexia
  • pneumonia
  • blood cholesterol increased
  • tachycardia
50-59:
  • granulocytopenia
  • pyrexia
  • agranulocytosis
  • death
  • leukopenia
  • white blood cell count increased
  • white blood cell count decreased
  • fall
  • confusional state
  • neutrophil count decreased
60+:
  • granulocytopenia
  • death
  • pneumonia
  • white blood cell count decreased
  • leukopenia
  • neutrophil count decreased
  • haemoglobin decreased
  • thrombocytopenia
  • neutropenia
  • confusional state

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Depakote er and Clozaril?

Can you answer these questions?

More questions for: Depakote er, Clozaril

You may be interested in these reviews

More reviews for: Depakote er, Clozaril

On eHealthMe, Depakote er (divalproex sodium) is often used to treat bipolar disorder. Clozaril (clozapine) is often used to treat schizophrenia. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.